American Society of Hirudotherapy

Tumor and Flap Reconstruction Volumes and Functional Outcomes after Glossectomy

Research article published in JAMA otolaryngology-- head & neck surgery (2026)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureWu et al. · JAMA otolaryngology-- head & neck surgery, 2026

Abstract

IMPORTANCE: Oral tongue is the most common subsite of oral cavity cancers, and incidence is increasing. Tongue resection is associated with morbidity, affecting speech, swallowing, and quality of life. OBJECTIVE: To assess the association of tumor volume and extent of tongue resection with functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: Patients with squamous cell carcinoma who underwent surgical resection of the oral tongue at a tertiary-level academic institution between 2014 and 2025 were included in this retrospective cohort study. Demographic, tumor, treatment, and postoperative outcomes measured with validated instruments were identified. EXPOSURE: Partial or hemiglossectomy (PG) vs total or subtotal glossectomy (TG). MAIN OUTCOMES AND MEASURES: Functional Oral Intake Scale (FOIS) score of 3 or lower, indicating gastrostomy tube dependency. Multivariable analysis assessed risk factors for the primary outcome. Radiographic volumetric analysis of tumor, tongue, and flap volumes was performed. Linear and nonlinear regression modeling assessed the association between measured volumes and functional outcomes. RESULTS: Of 357 patients (median age 62.3 [range, 18-95] years; 51.0% female), 88.2% [n=315] had PG and 11.8% [n=42] had TG. Tumors were classified as T1 or T2 in 71.2% of patients (254 of 357) and as T3 or T4 in 28.8% (103 of 357). Free-flap reconstruction was performed in 150 (42.0%) patients, and 186 (52.1%) received adjuvant radiation. Median follow-up was 36.1 (IQR, 18.2-65.6) months. The TG cohort had worse median FOIS score (2 [IQR, 1-5] vs 5 [IQR, 4-6]), aspiration (3 [IQR, 2-5] vs 1 [IQR, 1-2]), tongue strength (17 [IQR, 15-20] vs 36 [IQR, 25-42]), tongue range of motion (16 [IQR, 0-25] vs 88 [IQR, 63-100]), speech understandability (50 [IQR, 50-75] vs 100 [IQR, 100-100]), and patient-reported quality of life (67 [IQR, 60-71] vs 77 [IQR, 65-86]). On multivariable analysis, older age, current or former smoking status, use of free flap, TG, and greater resection volume were associated with FOIS score of 3 or lower. Preoperative tumor fraction greater than 31% and resection volume fraction greater than 67% were associated with the outcome of FOIS score of 3 or lower, indicating gastrostomy tube dependence. Preoperative tumor fraction greater than 26% and resection volume fraction greater than 58% were associated with understandability of speech score lower than 75, indicating poorly intelligible speech. On nonlinear regression analysis, tongue volume restoration to 100% of baseline value was associated with improved oral intake. CONCLUSIONS AND RELEVANCE: In this study, volumetric analysis demonstrated that tumor, resection, flap, and total tongue volumes were associated with speech and swallow outcomes. These findings suggest that quantitative knowledge of incremental changes in tongue resection and restoration may contribute to improved preoperative counseling and functional outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansGlossectomyFemaleRetrospective StudiesTongue NeoplasmsMiddle AgedAgedMaleAdultAged, 80 and overSurgical FlapsCarcinoma, Squamous CellPlastic Surgery ProceduresAdolescentYoung AdultTumor BurdenTreatment OutcomeQuality of Life

Summary

Retrospective cohort of 357 oral tongue squamous cell carcinoma patients found total or subtotal glossectomy and greater resection volume associated with gastrostomy-tube dependence, while restoring tongue volume to baseline was associated with improved oral intake.

Context

This retrospective cohort of 357 oral-tongue squamous-cell-carcinoma patients (2014-2025) used volumetric imaging to link tumor size, extent of glossectomy, and reconstructed flap volume to speech and swallowing outcomes, finding that total/subtotal glossectomy and greater resection volume fractions were associated with worse functional scores and gastrostomy-tube dependence, while restoring tongue volume toward baseline correlated with improved oral intake. The connection runs through free-flap head-and-neck reconstruction, performed in 42% of this cohort: such free flaps are a recognized setting for post-operative venous congestion in which medicinal leeches are sometimes used adjunctively to salvage a compromised flap, so this study illuminates the reconstructive stakes and the importance of flap viability that motivate leech rescue. The caveat is that this is a retrospective cohort focused on functional outcomes and volumetric prediction, not on flap complications or leech therapy, which it does not address at all; it provides procedural and outcomes context only and offers no direct evidence about hirudotherapy.

Citation

Reference (Vancouver style)

Wu SS, Jetly AS, Starmer HM, Finegersh A, Holsinger FC, Chen MM, et al. Tumor and Flap Reconstruction Volumes and Functional Outcomes after Glossectomy. JAMA Otolaryngol Head Neck Surg. 2026;152(5):513-522. doi:10.1001/jamaoto.2026.0099. PMID: 41854621

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.